TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells

Inflammasome‐associated cell death: Pyroptosis, apoptosis, and physiological implications

(2020) Kohsuke Tsuchiya   MICROBIOLOGY AND IMMUNOLOGY

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors

(2020) Sohaib Nizami et al.   IMMUNOLOGY

Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases

(2019) Carolina Pellegrini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Expanding the Organismal Proteostasis Network: Linking Systemic Stress Signaling with the Innate Immune Response

(2019) Jay Miles et al.   TRENDS IN BIOCHEMICAL SCIENCES

AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation

(2019) Feng Li et al.   BIOCHEMICAL PHARMACOLOGY

4-HNE induces proinflammatory cytokines of human retinal pigment epithelial cells by promoting extracellular efflux of HSP70

(2019) Hua-jing Yang et al.   EXPERIMENTAL EYE RESEARCH

Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome

(2018) Niina Piippo et al.   Scientific Reports

The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease

(2018) Abdullah Hoter et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of Heat Shock Protein 90 by 17-AAG Reduces Inflammation via P2X7 Receptor/NLRP3 Inflammasome Pathway and Increases Neurogenesis After Subarachnoid Hemorrhage in Mice

(2018) Yuchun Zuo et al.   Frontiers in Molecular Neuroscience

P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy

(2017) Mahmoud G. Khalafalla et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in Rats

(2017) Zhijuan Mao et al.   NEUROCHEMICAL RESEARCH

Pharmacokinetic aspects of retinal drug delivery

(2017) Eva M. del Amo et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Inflammation and its role in age-related macular degeneration

(2016) Anu Kauppinen et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Inflammasome priming increases retinal pigment epithelial cell susceptibility to lipofuscin phototoxicity by changing the cell death mechanism from apoptosis to pyroptosis

(2016) Carolina Brandstetter et al.   JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Interleukin-1β Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV)

(2015) Min Zhao et al.   PLoS One

Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells

(2014) Niina Piippo et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

(2014) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

(2014) R Suzuki et al.   LEUKEMIA

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90  and  , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

(2014) S. Ohkubo et al.   MOLECULAR CANCER THERAPEUTICS

Oxidative Stress Protection by Exogenous Delivery of rhHsp70 Chaperone to the Retinal Pigment Epithelium (RPE), a Possible Therapeutic Strategy Against RPE Degeneration

(2014) Astrid Subrizi et al.   PHARMACEUTICAL RESEARCH

Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration

(2013) Kai Kaarniranta et al.   Autophagy

First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

(2013) C. Sessa et al.   CLINICAL CANCER RESEARCH

Hsp90 inhibition protects against inherited retinal degeneration

(2013) Mònica Aguilà et al.   HUMAN MOLECULAR GENETICS

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

A2E Induces IL-1ß Production in Retinal Pigment Epithelial Cells via the NLRP3 Inflammasome

(2013) Owen A. Anderson et al.   PLoS One

DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88

(2012) Valeria Tarallo et al.   CELL

Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction

(2012) Kate Schroder et al.   IMMUNOBIOLOGY

Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells—Implications for age-related macular degeneration (AMD)

(2012) Anu Kauppinen et al.   IMMUNOLOGY LETTERS

NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components

(2012) Sarah L Doyle et al.   NATURE MEDICINE

The determination and interpretation of the therapeutic index in drug development

(2012) Patrick Y. Muller et al.   NATURE REVIEWS DRUG DISCOVERY

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

(2011) Simon Pacey et al.   CLINICAL CANCER RESEARCH

The Inflammasomes

(2010) Kate Schroder et al.   CELL

Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases

(2010) Guang Luo et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

(2010) Lawrence C.S. Tam et al.   HUMAN MOLECULAR GENETICS

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Cis-urocanic acid suppresses UV-B-induced interleukin-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro

(2009) J VIIRI et al.   ACTA OPHTHALMOLOGICA

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

(2009) Shivaani Kummar et al.   EUROPEAN JOURNAL OF CANCER

Cutting Edge: NF- B Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression

(2009) F. G. Bauernfeind et al.   JOURNAL OF IMMUNOLOGY

Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death

(2008) Raphael Beck et al.   BIOCHEMICAL PHARMACOLOGY

Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells

(2008) Tuomas Ryhänen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The NALP3 inflammasome is involved in the innate immune response to amyloid-β

(2008) Annett Halle et al.   NATURE IMMUNOLOGY